Stryker Recalled The Cartiva Implant

2016            FDA approves Cartiva Synthetic Cartilage Implant
2018            Stryker acquires Cartiva Inc.
2020 to 2024    Patient complaints and failure reports mount
October 2024    Stryker issues Class II FDA recall
Late 2025       Lawsuits filed across federal courts nationwide
February 2026   JPML consolidates cases into MDL 3172
                Eastern District of Arkansas, Judge Kristine G. Baker
Today           14+ cases pending in MDL. Numbers growing.

A Class II recall means the FDA determined the device may cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote. In plain terms, the device was found to be defective enough that patients are at risk.

If you received a Cartiva implant and you are experiencing any of the following, you may have legal grounds to file a claim:

• Ongoing pain in the big toe
• Stiffness or reduced range of motion
• A sense the implant has shifted or settled
• Recommendation for revision surgery
• Recommendation for fusion surgery

Independent post market data has shown Cartiva failure rates as high as 64% in some patient populations, far above the rates Cartiva originally reported in pre approval studies. Plaintiffs in MDL 3172 allege that the manufacturer knew or should have known the device would fail at these rates and failed to warn patients and surgeons.

1. Talk to your surgeon about whether you have a Cartiva. Many patients do not know the brand of their implant.
2. Get a copy of your operative report. It will list the device by brand.
3. Contact the Baker Legal Team for a free case review. No fees unless we win.